Quick Answer
Apogee Therapeutics, Inc. reported R&D Expense of $214.71 million for fiscal year 2025.
Apogee Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $214.71M | +27.9% |
| 2024 | $167.87M | +145.3% |
| 2023 | $68.42M | +146.3% |
| 2022 | $27.79M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $54.18M | +18.5% | -2.7% |
| June 30, 2025 | $55.70M | +67.7% | +20.1% |
| March 31, 2025 | $46.39M | +61.5% | +1.5% |
| September 30, 2024 | $45.71M | +167.8% | +37.7% |
| June 30, 2024 | $33.21M | +138.1% | +15.6% |
| March 31, 2024 | $28.72M | +239.6% | +68.2% |
| September 30, 2023 | $17.07M | +72.7% | +22.4% |
| June 30, 2023 | $13.95M | +863.1% | +64.9% |
- Apogee Therapeutics, Inc. showed an increase of +27.9% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Apogee Therapeutics, Inc.’s r&d expense has grown by 672.7% (from $27.79 million to $214.71 million).
- The most recent figure is from Apogee Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: